Global Autoimmune Disease Therapeutics Market Size, Share, Growth Analysis Report - Forecast 2034

Autoimmune Disease Therapeutics Market Size

The global autoimmune disease therapeutics market size was worth around USD 123.96 Billion in 2024 and is predicted to grow to around USD 249.71 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 7.4% between 2025 and 2034.

The report analyzes the global autoimmune disease therapeutics market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the autoimmune disease therapeutics industry.

Request Free Sample

Autoimmune Disease Therapeutics Market: Overview

Autoimmune illnesses are brought on by an autoimmune reaction that targets cells and destroys body tissue. Autoimmune disorders are nearly incurable and without a permanent cure. There are about 80 autoimmune disorders around the globe with unidentified causes. Over 300 million people worldwide have this condition, and between 70 and 80% of those sufferers are female. The two main drivers driving the market's expansion are the increased prevalence of autoimmune illnesses and the expanding understanding of these conditions. Over the projected period, the market development for autoimmune disease therapeutics is expected to be further bolstered by the expansion of autoimmune disease research and the rise in autoimmune disease therapeutic usage.

Furthermore, technological developments in screening processes, widespread availability of therapeutics, and the significant presence of pipeline medications such as secukinumab, tocilizumab, certolizumab, tofacitinib, etanercept, and others are projected to have a positive impact on the market growth. The critical barriers to the worldwide autoimmune disease therapeutics market, however, include the lack of funding for developing nations, the high cost of treating the disease, the lack of availability of the medication in developing countries, and the development of substitute technologies. A stringent regulatory process and increasing treatment side effects are further factors that are expected to limit market expansion.

Key Insights

• As per the analysis shared by our research analyst, the global autoimmune disease therapeutics market is estimated to grow annually at a CAGR of around 7.4% over the forecast period (2025-2034).
• Regarding revenue, the global autoimmune disease therapeutics market size was valued at around USD 123.96 Billion in 2024 and is projected to reach USD 249.71 Billion by 2034.
• The autoimmune disease therapeutics market is projected to grow at a significant rate due to rising prevalence of autoimmune disorders, advancements in biologic and targeted therapies, increasing R&D investments, and growing demand for personalized medicine.
• Based on Drug Class, the Immunosuppressants segment is expected to lead the global market.
• On the basis of Distribution Channel, the Hospitals segment is growing at a high rate and will continue to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Request Free Sample

Autoimmune Disease Therapeutics Market: Growth Drivers

The growing prevalence of several autoimmune disorders drives the global market growth.

Factors contributing to the global autoimmune disease therapy market's growth include rising autoimmune disease prevalence, more patient awareness, and increased laboratory automation, which allows for the simultaneous diagnosis of several diagnostic tests, resulting in faster and more accurate findings thereby increasing patient awareness of such disorders fuels market expansion. Autoimmune illness targets healthy tissues, cells, and organs. It can affect any body area, weakening body function and threatening life. These illnesses sometimes need lifetime treatment to control symptoms because there is no known cure. Compared to men, women develop autoimmune diseases significantly more quickly. The condition is estimated to be one of the top ten causes of death among women under 65 and the second leading cause of chronic illness. Additionally, in the U.S., it is the leading cause of morbidity for women. There are currently over 80 clinically distinct types of autoimmune disorders. As a result, the autoimmune disease treatments market will expand throughout the forecast period.

Autoimmune Disease Therapeutics Market: Restraints

Lack of funding and high costs associated with treating the diseases may hamper the global market growth.

The key factors holding back the worldwide market for autoimmune disease therapies include insufficient funding in developing nations, the high cost of treating the condition, the lack of medication availability in developing countries, and the development of alternative technologies. The lack of understanding and awareness of autoimmune illnesses and their symptoms in poor & distant places would reduce their utilization in undeveloped and lower-income nations.

Autoimmune Disease Therapeutics Market: Opportunities

Improvements in healthcare infrastructure and technology bring up several growth opportunities.

Technology advancements such as the creation of novel biomarkers like Humira and Enbrel, compact diagnostic point-of-care devices, and growing preference for laboratory robotics are predicted to fuel growth throughout the forecast period. There is a surge in the sector due to constantly improving healthcare infrastructure and rising healthcare spending. Adopting sophisticated technology for improved treatment may pique more people’s attention in applying the medicine. The market value for treatments for autoimmune diseases might rise with higher adoption rates. Increased government spending on better medical facilities has several potential benefits for market expansion. New competitors may have chances in the worldwide market for treating autoimmune diseases due to the increased accessibility of biosimilar medications and more economical treatments.

Autoimmune Disease Therapeutics Market: Challenges

• Quality and safety of autoimmune illness control therapy continue to be a global challenge: The quality and safety of autoimmune disorder control therapy may pose a challenge to the growth of the global autoimmune disease treatment market. The high cost of treatment is a significant disadvantage for the autoimmune disease diagnosis and treatment market share, and inadequate infrastructure in low-income geographic areas will slow illness syndrome treatment market growth.
• Lack of awareness and skilled professionals for therapeutic procedures: Lack of knowledge and skilled workers may challenge market expansion. Lack of knowledge among the populace in any area can disregard the disease's subsequent, potentially lethal treatments. Some regions have poor healthcare facilities.

Autoimmune Disease Therapeutics Market: Segmentation

The global autoimmune disease therapeutics market is segregated based on drug class, distribution channel, and region.

By drug class, the market is divided into immunosuppressants, anti-inflammatory drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, and biologics. Among these, the anti-inflammatory drugs segment dominates the market, accounting for more than 30% of global sales.

By distribution channel, the market is classified into hospitals, clinics, drug stores, and independent pharmacies. Over the forecast period, the hospital segment is expected to develop faster.

Autoimmune Disease Therapeutics Market: Report Scope

Recent Developments

• January 2021 - Exagen Inc., an organization, committed to revolutionizing the care continuum for patients with autoimmune illnesses, stated that all AVISE test options (SLE Prognostic, Lupus, CTD, SLE Monitor, APS, MTX, Vasculitis AAV, and HCQ) were signed in-network service with Tufts Health Center, an esteemed academic medical center on a global scale.
• August 2019 - The U.S. FDA authorized PerkinElmer, Inc.'s EUROIMMUN Anti-Tissue Transglutaminase ELISA to help doctors determine whether to confirm or rule out a diagnosis of celiac disease.

Autoimmune Disease Therapeutics Market: Regional Landscape

Increasing government initiatives will help North America dominate the global market.

North America dominates the global autoimmune disease therapeutics market and accounted for more than 42.4% of the worldwide revenue in 2021. This is due to the rising prevalence of autoimmune diseases and the increased presence of government programs such as the Patient Protection Act and the Affordable Care Act. The market in this region is expanding due to rising healthcare spending, improved healthcare infrastructure, increased use of new technology, and the presence of significant vital players. The cost of treating autoimmune diseases is estimated to reach USD 100 billion annually in the United States, according to National Institute of Health estimates.

Over the forecast period, Europe is expected to be the fastest-growing regional market. The rising incidence of autoimmune diseases, expanding government efforts to upgrade the healthcare system, and increased adoption of cutting-edge technologies like portable diagnostic tools and novel biomarkers will all contribute to the expansion of the European market. High R&D activities, combined with the country's growing economic burden of autoimmune disorders, would impact regional development. Increased demand for more reliable diagnoses of systemic and localized diseases will also benefit the market.

Autoimmune Disease Therapeutics Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the autoimmune disease therapeutics market on a global and regional basis.

The global autoimmune disease therapeutics market is dominated by players like:

• Magic Leap
• Immersion
• Apple
• Daqri LLC
• Sony
• Blippar
• Microsoft
• Wikitude
• Google
• PTC
• CyberGlove Systems Inc.
• Infinity Augmented Reality
• Eon Reality Inc.
• ODG
• and Samsung Electronics

The global autoimmune disease therapeutics market is segmented as follows;

By Drug Class

• Immunosuppressants
• Anti-Inflammatory Drugs
• Corticosteroids
• Nonsteroidal Anti-Inflammatory Drugs
• and Biologics

By Distribution Channel

• Hospitals
• Clinics
• Drug Stores
• and Independent Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America